Influences of allergic rhinitis on sleep

Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 5, 2004, Pages 617-629

  Ferguson, Berrylin J ^a,b,c  

^a Univ of Pittsburgh Medical Center ^*

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARACHIDONIC ACID; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CYTOKINE; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE; HISTAMINE; INTERLEUKIN 4; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; OXYMETAZOLINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PRANLUKAST; PROSTAGLANDIN; PROSTAGLANDIN D2; PSEUDOEPHEDRINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC RHINITIS; BURNING SENSATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DRUG EFFICACY; EPISTAXIS; GLAUCOMA; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; NONHUMAN; NONREM SLEEP; NOSE CONGESTION; NOSE OBSTRUCTION; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PRURITUS; QUALITY OF LIFE; REM SLEEP; RESTLESSNESS; REVIEW; RHINOMETRY; RHINORRHEA; SEDATION; SLEEP DISORDER; SNEEZING; TACHYCARDIA; THYROTOXICOSIS; TREMOR; XEROSTOMIA;

EID: 2442674124     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2004.02.001     Document Type: Review

References (73)

1. Lierl MB. Allergy of the upper respiratory tract. In: Lawlor GM Jr, Fischer TJ, Adelman DC, editors. Manual of allergy and immunology. 3rd ed. Boston (MA): Little. Brown and Company; 1995:p. 94-111.
2. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997;99:S757-62.
3. McNicholas WT, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982;126:625-8.
4. Craig TJ, Teets S, Lehman EB, et al. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998;101:633-7.
5. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003;58:380-5.
6. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci 2001;933:201-10.
7. Krouse HJ, Davis JE, Krouse JH. Immune mediators in allergic rhinitis and sleep. Otolaryngol Head Neck Surg 2002;126:607-13.
8. Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S750-6.
9. Craig TJ, Mende C, Hughes K, et al. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc 2003;24:53-8.
10. Hayden ML. Allergic rhinitis: a growing primary care challenge. J Am Acad Nurse Pract 2001;13:545-51; quiz 552-44.
11. Kessler RC, Almeida DM, Berglund P, et al. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:289-95.
12. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6.
13. Janson C, De Backer W, Gislason T, et al. Increased prevalence of sleep disturbances and daytime sleepiness in subjects with bronchial asthma: a population study of young adults in three European countries. Eur Respir J 1996;9:2132-8.
14. Houser SM, Mamikoglu B, Aquino BF, et al. Acoustic rhinometry findings in patients with mild sleep apnea. Otolaryngol Head Neck Surg 2002;126:475-80.
15. Kramer MF, De La Chaux R, Dreher A, et al. Allergic rhinitis does not constitute a risk factor for obstructive sleep apnea syndrome. Acta Otolaryngol 2001;121:494-9.
16. Reinberg A, Gervais P, Levi F, et al. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol 1988;81:51-62.
17. Smolensky MH, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol 1995;95:1084-96.
18. Rundcrantz H. Postural variations of nasal patency. Acta Otolaryngol 1969;68:435-43.
19. Marshall L, Born J. Brain-immune interactions in sleep. Int Rev Neurobiol 2002;52:93-131.
20. Lavie P, Gertner R, Zomer J, et al. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol 1981;92:529-33.
21. McColley SA, Carroll JL, Curtis S, et al. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 1997;111:170-3.
22. Mamikoglu B, Houser SM, Corey JP. An interpretation method for objective assessment of nasal congestion with acoustic rhinometry. Laryngoscope 2002;112:926-9.
23. American Academy of Allergy, Asthma & Immunology, Inc. The Allergy Report. Overview of allergic diseases: Diagnosis, management and barriers to care. Vol 1. Milwaukee (WI): The Academy; 2000.
24. White M. Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 1999;103:S378-81.
25. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999;103:S382-5.
26. Juliusson S, Pipkorn U, Karlsson G, et al. Mast cells and eosinophils in the allergic mucosal response to allergen challenge: changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol 1992;90:898-909.
27. Pearce FL. Biological effects of histamine: an overview. Agents Actions 1991;33:4-7.
28. Tamaoki J, Nakata J, Takeyama K, et al. Histamine H2 receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes. J Allergy Clin Immunol 1997;99:233-8.
29. Rajakulasingam K, Polosa R, Lau LC, et al. Comparative nasal effects of bradykinin and histamine: influence on nasal airways resistance and plasma protein exudation. Thorax 1993;48:324-9.
30. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14.
31. Okuda M, Watase T, Mezawa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
32. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-97.
33. Miadonna A, Tedeschi A, Leggieri E, et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357-62.
34. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol 2000;84:176-85; quiz 185-77.
35. Sri Kantha S, Matsumura H, Kubo E, et al. Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukotriene Essent Fatty Acids 1994;51:87-93.
36. Obal FJ, Krueger JM. Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci 2003;8:D520-50.
37. Arimura A, Yasui K, Kishino J, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, s-5751. J Pharmacol Exp Ther 2001;298:411-9.
38. Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 1990;86:924-35.
39. Proud D, Reynolds CJ, Lacapra S, et al. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 1988;137:613-6.
40. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313:65-70.
41. Rubinstein I. Nasal inflammation in patients with obstructive sleep apnea. Laryngoscope 1995;105:175-7.
42. Devillier P, Dessanges JF, Rakotosihanaka F, et al. Nasal response to substance P and methacholine in subjects with and without allergic rhinitis. Eur Respir J 1988;1:356-61.
43. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997;52:12-8.
44. Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041-9.
45. Calhoun WJ. Nocturnal asthma. Chest 2003;123:399S-405S.
46. Aoyagi M, Watanabe H, Sekine K, et al. Circadian variation in nasal reactivity in children with allergic rhinitis: correlation with the activity of eosinophils and basophilic cells. Int Arch Allergy Immunol 1999;120(suppl 1):95-9.
47. Kraft M, Vianna E, Martin RJ, et al. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 1999;103:66-71.
48. Bellia V, Bonanno A, Cibella F, et al. Urinary leukotriene E4 in the assessment of nocturnal asthma. J Allergy Clin Immunol 1996;97:735-41.
49. Morrison JF, Pearson SB, Dean HG. Parasympathetic nervous system in nocturnal asthma. Br Med J (Clin Res Ed) 1988;296:1427-9.
50. Lung MA. The role of the autonomic nerves in the control of nasal circulation. Biol Signals 1995;4:179-85.
51. Loehrl TA, Smith TL, Darling RJ, et al. Autonomic dysfunction, vasomotor rhinitis, and extraesophageal manifestations of gastroesophageal reflux. Otolaryngol Head Neck Surg 2002;126:382-7.
52. American Academy of Allergy, Asthma & Immunology, Inc. The Allergy Report. Diseases of atopic diathesis. Vol 2. Milwaukee (WI): The Academy; 2000.
53. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Eur Acad Allergol Clin Immun Allergy 2000;55:116-34.
54. Chonmaitree T, Saeed K, Uchida T, et al. A randomized, placebo-controlled trial of the effect of antihistamine or corticosteroid treatment in acute otitis media. J Pediatr 2003;143:377-85.
55. Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin Allergy Immunol 2002;17:337-88.
56. Golden S, Teets SJ, Lehman EB, et al. Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:53-7.
57. Saengpanich S, Assanasen P, de Tineo M, et al. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope 2002;112:47-52.
58. Astelin [package insert]. Somerset (NJ): MedPointe Pharmaceuticals. Available at: http//www.astelin.com/productinfo/pi.html. Accessed September 15, 2003.
59. Jen A, Baroody F, de Tineo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:732-8.
60. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598-604.
61. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23.
62. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407-13.
63. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22.
64. Ratner PH, Howland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003;90:536-42.
65. FDA. Drug shortages. Center for Drug Evaluation and Research. Available at: http://www.fda.gov/eder/drug/shortages/default.htm. Accessed September 15, 2003.
66. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8.
67. Numata T, Konno A, Yamakoshi T, et al. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-73.
68. Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
69. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600.
70. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8.
71. van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22.
72. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001;31:61-8.
73. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:344-9.